Current Projects

Our projects advance the understanding of psoriasis, improve patient care and support the next generation of psoriasis leaders.

Biosimilars Working Group Impacting how biosimilars will improve access to care

International Fellowship Program

Fostering the generation of psoriasis leaders

Global Psoriasis Atlas Comprehensive global database on psoriasis

Latin America Working GroupImproving care for patients in Latin America

P4 Medicine Promoting better care systems

Palmoplantar Psoriasis Developing better treatment methods

Publications Advancing knowledge

Scientific Symposia Promoting scientific collaboration

Severity Classification Defining disease severity classification

IPC Psoriasis Review Newsletter

IPC's bi-annual review of the latest manuscripts in the field of psoriasis.

Read the latest issue

Psoriasis News

Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with Moderate to Severe Plaque Psoriasis

8/20/2019 10:08:00 AM

Eli Lilly and Company (NYSE: LLY) announced that Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO).

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

8/6/2019 11:36:00 AM

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.

Updated Disease Classification System Adopted by the World Health Organization

8/1/2019 7:19:00 AM

On 25 May 2019, the World Health Assembly officially adopted the eleventh revision of the International Classification of Diseases (ICD-11). The ICD-11 will come into effect on 1 January 2022.

FDA Approves Samsung Bioepis' HADLIMA™ (adalimumab-bwwd)

8/1/2019 7:09:00 AM

Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab)i , for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis, and plaque psoriasis. Please see full indications and Boxed Warning for HADLIMA™, below.

More News

Current Projects

Biosimilars Working Group Impacting how biosimilars will improve access to care

Fostering the generation of psoriasis leaders

The mechanistic model(s) of psoriasis: Autoimmune and/or inflammatory?

Psoriasis News

Advancing Knowledge. Enhancing Care.

Current Projects

Biosimilars Working GroupImpacting how biosimilars will improve access to care

Fostering the generation of psoriasis leaders

The mechanistic model(s) of psoriasis: Autoimmune and/or inflammatory?

Psoriasis News

Advancing Knowledge. Enhancing Care.

Biosimilars Working Group Impacting how biosimilars will improve access to care